Candriam Luxembourg S.C.A. grew its stake in Radius Health, Inc. (NASDAQ:RDUS) by 23.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 142,000 shares of the biopharmaceutical company’s stock after purchasing an additional 27,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.32% of Radius Health worth $5,474,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of RDUS. BlackRock Inc. lifted its holdings in shares of Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after purchasing an additional 2,628,070 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after purchasing an additional 569,300 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Radius Health in the second quarter valued at approximately $25,589,000. BB Biotech AG lifted its holdings in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares in the last quarter. Finally, RA Capital Management LLC bought a new position in shares of Radius Health in the second quarter valued at approximately $22,486,000.
A number of analysts recently commented on RDUS shares. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Cantor Fitzgerald set a $65.00 price target on Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a research report on Monday, July 31st. BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. Radius Health presently has a consensus rating of “Hold” and a consensus target price of $51.00.
In related news, major shareholder Growth N. V. Biotech purchased 50,000 shares of Radius Health stock in a transaction dated Friday, November 3rd. The stock was bought at an average cost of $29.15 per share, for a total transaction of $1,457,500.00. Following the completion of the transaction, the insider now owns 5,648,799 shares in the company, valued at $164,662,490.85. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jesper Hoiland purchased 6,800 shares of Radius Health stock in a transaction dated Tuesday, November 7th. The stock was bought at an average price of $29.04 per share, with a total value of $197,472.00. Following the completion of the transaction, the insider now owns 12,900 shares of the company’s stock, valued at approximately $374,616. The disclosure for this purchase can be found here. Insiders acquired 425,900 shares of company stock valued at $14,380,354 over the last three months. Company insiders own 15.00% of the company’s stock.
Radius Health, Inc. (NASDAQ RDUS) traded down $0.30 during trading hours on Monday, reaching $28.10. The company’s stock had a trading volume of 1,288,900 shares, compared to its average volume of 961,724. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health, Inc. has a twelve month low of $27.16 and a twelve month high of $55.97.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period in the prior year, the company earned ($1.07) earnings per share. equities research analysts predict that Radius Health, Inc. will post -5.4 EPS for the current fiscal year.
Radius Health Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.